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Abstract: Chronic myeloid leukemia (CML) is a stem cell disease, in which the BCR/ABL 
oncoprotein is considered essential for abnormal growth and accumulation of neoplastic 
cells. During the past 10 years, the BCR/ABL tyrosine kinase inhibitor imatinib (STI571) 
has successfully been introduced in the treatment of the disease. However, intrinsic as well 
as acquired resistance against the drug have been described and have been recognized as an 
emerging problem and challenge in clinical practice, and a key issue in CML research. Most of 
the respective concepts focus on imatinib-resistant mutants of BCR/ABL that are detectable in 
a high proportion of cases. However, other factors also contribute to resistance against imatinib, 
including the genetic background, the biologic features of CML stem cells, gene ampliﬁ  cations, 
silencing of tumor suppressor genes, and various pharmacologic aspects. In this article, the 
mechanisms of resistance against imatinib and other BCR/ABL tyrosine kinase inhibitors in 
CML are discussed together with strategies to overcome and to prevent resistance with available 
drugs or with novel antileukemic approaches.
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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the 
t(9; 22) and the related oncogene, BCR/ABL (Nowell and Hungerford 1960; Rowley 
1973; de Klein et al 1982). The respective fusion gene product, BCR/ABL, is a 
cytoplasmic 210 kDa protein that is considered essential for growth and survival of 
leukemic cells (Daley et al 1990; Lugo et al 1990; Gishizky and Witte 1992; Wetzler 
et al 1993; Biernaux et al 1995; Ren 2005). BCR/ABL displays constitutive tyrosine 
kinase (TK) activity and triggers a number of downstream signalling molecules 
including phosphoinositide 3-kinase (PI3K), mitogen-activated protein (MAP) kinase, 
nuclear factor-κB (NFκB), RAS, and signal transducer of activation and transcription 
5 (STAT5) (Pendergast et al 1993; Puil et al 1994; Skorski et al 1997; Sillaber et al 
2000; Sattler and Grifﬁ  n 2003; Melo and Deininger 2004; Van Etten 2007). These 
signalling molecules and pathways supposedly act together to promote malignant 
transformation, to enhance genetic instability, and to suppress apoptosis in leukemic 
cells (Hoover et al 2001; Melo and Deininger 2004; Van Etten 2007).
The (natural) clinical course in CML can be divided into a chronic (early) phase (CP), 
in which cellular differentiation and maturation are largely preserved, an accelerated phase 
(AP) of the disease, and a terminal (=blast) phase of CML (CML-BP), which resembles 
acute leukemia (Cortes and Kantarjian 2003; Giles et al 2004; Cortes et al 2006). In addi-
tion, based on the detection of BCR/ABL in apparently healthy subjects, a prephase of 
CML (with normal leukocyte counts), in which clonal BCR/ABL+ stem cells expand and 
generate subclones (Biernaux et al 1995; Bose et al 1998), has been postulated (Figure 1). Biologics: Targets & Therapy 2007:1(4) 434
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Figure 1 Evolution of CML with prephases—a proposed hypothesis.
Abbreviations: Ph, Philadelphia chromosome; CML, chronic myeloid leukemia; AML, acute myeloid leukemia.
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What hits drive BCR/ABL-positive cells (subclones) from a 
prephase into overt CML, remains at present unknown. It also 
remains uncertain whether a ‘pre-BCR/ABL-phase’ of CML 
exists, in which monoclonal but preleukemic stem cell clones 
develop and expand to provide a suitable cellular background 
for the establishment of a BCR/ABL+ clone (Figure 1). This 
hypothesis has been based on rare cases of BCR/ABL-negative 
but apparently monoclonal populations of leukemic cells (sub-
clones) that may develop in CML patients during treatment with 
imatinib. All in all, BCR/ABL is considered a most critical fac-
tor, but may per se not be sufﬁ  cient for disease-initiation. Also, 
whereas in CP, BCR/ABL is considered to play a predominant 
role for leukemia cell survival, additional pro-oncogenic 
molecules and pathways may become (more) important and 
contribute to malignant growth and thus disease-progression in 
advanced CML (AP, BP) (Shet et al 2002; Sattler and Grifﬁ  n 
2003; Calabretta and Perrotti 2004; Melo and Barnes 2007) 
(Figure 1).
The leukemic clone in CML is organized hierarchically, 
with more mature cells that have a limited capacity to divide 
and to survive, and cells with unlimited capacity to divide 
and to self-renew, so-called leukemic stem cells (Eaves et al 
1993, 1998; Holyoake et al 2000, 2001; Eisterer et al 2005; 
Elrick et al 2005). Taking this concept into consideration, 
it seems clear that the clinically relevant portion of MRD 
and any resulting relapse derives from CML stem cells, 
and that therapy is curative only when eradicating these 
cells. During disease evolution and probably even before 
overt disease is diagnosed (prephase of CML), CML stem 
cells may acquire multiple (transforming) hits, resulting 
in subclone-formation (Holyoake et al 2002; Jiang et al 
2007a). Therefore, the CML clone supposedly is composed 
of several different subclones at diagnosis in most (if not 
all) patients, a hypothesis that explains the ´occurrence´ of 
drug-resistant BCR/ABL-mutants during therapy through 
subclone-selection (Roche-Lestienne et al 2002; Jiang et al 
2007a). An unresolved question is why wild type (wt) BCR/
ABL-bearing cells have a growth advantage over subclones 
exhibiting BCR/ABL-mutants. In fact, in most patients, 
the mutant subclone is only detectable after initiation of 
BCR/ABL-targeting therapy. A related question is how the 
disease can suppress growth of normal hematopoietic stem 
cells. Here, one hypothesis is, that stem cell-derived nega-
tive growth-regulators (chalones) such as lipocalin, suppress 
growth of normal (stem) cells through a speciﬁ  c receptor, 
whereas CML stem cells are resistant, as they display only 
low amounts or lack lipocalin-binding sites (Devireddy et al 
2005; Lin et al 2005). Whether mutant BCR/ABL-bearing 
subclones are also suppressed by leukemic cells displaying 
wt BCR/ABL through chalone-dependent inhibition or other 
mechanisms, remains unknown.
The BCR/ABL kinase inhibitor imatinib has successfully 
been introduced in the treatment of CML. Thus, imatinib 
induces major cytogenetic responses in a majority of all 
patients with CP CML (Druker et al 2001a; Kantarjian H et al 
2002; Barbany et al 2002; O’Brien et al 2003). Responses 
are also seen in (some) patients with AP or BP (Druker et al 
2001b; Talpaz et al 2002; Kantarjian et al 2002; Sawyers 
et al 2002). However, despite overwhelming initial data and 
high expectations, little is known about long-term effects of 
imatinib (Druker et al 2006). An apparent result from follow 
up studies is that imatinib is unable to eradicate all neoplas-
tic stem cells (subclones) in CML. Rather, many patients 
develop overt resistance against imatinib during therapy, 
which is often associated with the outgrowth of subclones 
bearing mutations in BCR/ABL (Branford et al 2002, 2003; 
Kantarjian et al 2006a; Hochhaus et al 2007a). For such 
patients, treatment options are usually limited. In fact, many 
of them are in AP or BP, and only a subgroup of them are 
eligible for stem cell transplantation (SCT).
Therefore, a number of attempts have been made to 
identify new drugs that act antileukemic in imatinib-resistant 
CML (Shah et al 2004; Weisberg et al 2005, 2007b; O’Hare 
et al 2005; Martinelli et al 2005). Such drugs are directed 
against BCR/ABL and its mutants, but may also be directed 
against other (BCR/ABL-independent) molecules that play 
a role in malignant transformation (Martinelli et al 2005; 
Weisberg et al 2007b). Thus, molecular resistance against 
imatinib may not only be caused by changes in BCR/ABL, 
but also by other pro-oncogenic molecules (Kantarjian et al 
2006a; Hochhaus et al 2007a). Therefore, less speciﬁ  c tar-
geted drugs and combinations of targeted drugs have been 
proposed, and are currently applied in clinical trials to over-
come resistance. Some of the emerging TK inhibitors act on 
BCR/ABL as well as on other key signalling targets, such 
as Lyn or/and other Src kinases (Shah et al 2004; Martinelli 
et al 2005; Kimura et al 2005; Weisberg et al 2007b).
Apart from molecular resistance against imatinib, other 
mechanisms that cause resistance in CML, have also been 
described. First, immature leukemic cells (stem cells) 
may exhibit intrinsic (BCR/ABL-independent) resistance 
(Barnes and Melo 2006; Jiang et al 2007b). Second, a 
number of cellular molecules involved in the regulation of 
drug-uptake, drug-metabolism or drug-efﬂ  ux, may inﬂ  uence 
the bio-availability of imatinib (Herweijer et al 1990; 
Illmer et al 2004; Thomas et al 2004; Wang et al 2007; Biologics: Targets & Therapy 2007:1(4) 436
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be associated with reduced drug-uptake and increased drug-
efﬂ  ux. In particular, compared to more mature clonal cells, 
CML stem cells (CD34+/CD38-/Lin-) apparently display 
decreased levels of organic cation transporter-1 (OCT-1), a 
surface transporter involved in the uptake of imatinib, and 
increased levels of drug-efﬂ  ux-related surface molecules 
including the multi-drug resistance protein-1 (MDR-1), 
known to mediate the efﬂ  ux of imatinib (Jiang et al 2007b). 
Efﬂ  ux mechanisms may also contribute to resistance against 
other drugs including new BCR/ABL TK inhibitors, such as 
nilotinib (AMN107) (Brendel et al 2007). More recently, it 
has been described, that dasatinib may act better on imma-
ture CML (stem) cells compared to imatinib, but still may 
not be capable of killing all leukemic stem cells (subclones) 
(Copland et al 2006). An interesting approach to measure the 
response to imatinib on a qualitative basis and to possibly 
predict the response (and relapse) in progenitor compart-
ments, are recently proposed mathematical models (Michor 
et al 2005; Roeder et al 2006). It may be an interesting idea 
Brendel et al 2007). Lastly, more and more data suggest that 
imatinib is not capable of entering all organ-compartments 
in vivo. Likewise, imatinib is unable to cross the blood-
brain barrier in amounts sufﬁ  cient to reach a pharmacologic 
drug concentration in the central nervous system (CNS) 
(Takayama et al 2002; Senior 2003; Dai et al 2003; Wolff 
et al 2003). Correspondingly, CNS relapses are increasingly 
described in CML patients treated with imatinib (Abruzzese 
et al 2003; Leis et al 2004; Bornhäuser et al 2004; Rajappa 
et al 2004; Rytting and Wierda 2004; Matsuda et al 2005; 
Pavlu et al 2005; Kim et al 2006; Aichberger et al 2007).
In the following sections, various types of resistance 
against imatinib are discussed together with possibilities to 
prevent or to overcome resistance with currently available 
drugs, combination strategies employing drugs and SCT, 
or future therapeutic approaches such as siRNA or immu-
notherapies.
Leukemic stem cells exhibit 
‘intrinsic resistance’
Most patients in CML CP enter a complete cytogenetic 
response (CCR) during treatment with imatinib (Druker 
et al 2001a; Kantarjian H et al 2002; Barbany et al 2002; 
O’Brien et al 2003). In many of these patients, BCR/ABL-
transcripts decrease to low or even undetectable levels over 
time (Barbany et al 2002; Hughes et al 2003; Druker et al 
2006). However, discontinuation of imatinib is usually fol-
lowed by a cytogenetic and hematologic relapse (Breccia 
et al 2006; Rousselot et al 2007). Based on this observation 
and other studies, it has been hypothesized that MRD in ima-
tinib-treated patients contains leukemic stem cells (clinically 
relevant subclones), and that these residual stem cells exhibit 
imatinib-resistance (Graham et al 2002; Bhatia et al 2003; 
Michor et al 2005; Goldman and Gordon 2006; Deininger 
2007). A remarkable aspect is that the relapsing subclones 
that reappear after discontinuation of imatinib usually display 
wt BCR/ABL. Therefore, apart from well known molecular 
mechanisms (BCR/ABL mutations) leading to resistance, 
stem cell resistance against imatinib in CML is also consid-
ered to result from stem cell-related (intrinsic) mechanisms. 
The exact molecular basis of intrinsic stem cell resistance 
against imatinib is not well understood. The different hypoth-
eses that have been raised are summarized in Table 1. Apart 
from stem cell quiescence and overexpression of BCR/ABL, 
these cells may also utilize BCR/ABL-independent survival 
mechanisms (Copland et al 2005; Copland et al 2006; Barnes 
and Melo 2006; Jiang et al 2007b). In addition, it has been 
hypothesized that imatinib-resistance in CML stem cells may 
Table 1 Resistance of CML stem cells against imatinib: Proposed 
hypotheses*
Observations Speciﬁ  c hypothesis/
 molecular  basis
Stem cell quiescence   G0 arrest by chalones or by speciﬁ  c
(dormance)  cell cycle regulators, quite similar
  mechanisms may lead to dormance
  of normal stem cells**
Stem cell plasticity  Development of subclones may be
  facilitated by mechanisms similar
  to those responsible for differentiation
  of normal myeloid stem cells into
  various myeloid lineages** – exact
  mechanisms are unknown
Overexpression of BCR/ABL  BCR/ABL mRNA and protein over-
  expression – mechanisms unknown
Speciﬁ  c BCR/ABL-induced stem  Altered DNA repair; hypermethylation;
cell deregulation  induction of stem cell subclones. Over
  time, BCR/ABL may overcome some of
  the stem cell-protecting mechanisms
BCR/ABL-independent survival  Stem cell-speciﬁ  c survival factors;
  altered survival factors in subclones***
Decreased uptake of imatinib  Decreased expression of OCT-1, a
  major transporter of imatinib
Increased drug efﬂ  ux  Overexpression of P-glycoprotein
  (MDR-1) and other efﬂ  ux pumps****
Notes: *Relate all to differences between CML stem cells and more mature CML 
cells. The following articles refer to these concepts: Copland et al 2005, 2006; Barnes 
and Melo 2006; Brendel et al 2007; Jiang et al 2007b); **The biology of normal stem 
cells and CML stem cells may be quite similar; ***CML stem cells may even survive 
after complete deactivation of BCR/ABL; ****Normal and neoplastic stem cells may 
defend their long-term existence against external ´enemies´ (toxins, drugs) by high 
toxin/drug efﬂ  ux.
Abbreviations: OCT-1, organic cation transporter; MDR-1, multidrug resistance 
gene-1.Biologics: Targets & Therapy 2007:1(4) 437
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to employ such models in forthcoming clinical trials studying 
new TK inhibitors or combination therapies.
As outlined above, stem cell resistance in CML is an 
emerging issue and major focus in clinical and preclinical 
research, and although it is difﬁ  cult to purify CML stem 
cells for in vitro investigations, the availability of sensitive 
MRD parameters offers a valuable basis for the design of 
clinical trials examining the effects of novel drugs and drug-
combinations on residual leukemic stem cells. For the near 
future, one of the most important questions will be whether 
any of the new TK inhibitors, like dasatinib, nilotinib, INNO-
406, or others, can induce long-lasting CCR and consecutive 
cure through eradication of all relevant CML stem cell sub-
clones in CP. Respective clinical trials employing dasatinib 
or nilotinib as frontline therapy in CML CP are in progress. 
These trials should reveal the exact curative potential of these 
drugs and thus will answer the question as to whether they 
can overcome ´intrinsic stem cell resistance´. It should be 
mentioned here that not all CML stem cell subclones may be 
of clinical relevance (causing relapse), and that some of these 
patients may stay in complete hematologic remission even if 
a BCR/ABL+(sub)clone is detectable (Griswold et al 2006; 
Khorashad et al 2006; Goldman and Gordon 2006).
The next important question would be whether combi-
nations of targeted drugs may (better) overcome stem cell 
resistance against imatinib. First, some of these combinations 
may facilitate the uptake of imatinib or other BCR/ABL TK 
inhibitors in CML stem cells, or may prevent enhanced drug 
efﬂ  ux from these cells (Mahon et al 2003; Thomas et al 2004; 
Illmer et al 2004). Likewise, a number of MDR-1 block-
ers (cyclosporin-A, verapamil, others) are available, and it 
may be an interesting approach to combine such inhibitors 
with imatinib or other BCR/ABL TK inhibitors to enhance 
intracellular drug levels in CML stem cells. More recently, it 
has been described that combinations of TK inhibitors with 
each other may also enhance intracellular levels of individual 
drugs and thereby may lead to cooperative (synergistic) 
antileukemic effects (White et al 2007). Indeed, most of the 
BCR/ABL TK inhibitors exert synergistic anti-leukemic 
effects on CML cells (Weisberg et al 2007a).
Another important aspect is that conventional antileu-
kemic drugs such as interferon-alpha, may have a more 
pronounced effect on CML progenitor cells compared with 
imatinib (Angstreich et al 2005; Verbeek et al 2006). There-
fore, several trials employ combinations between interferon-
alpha and BCR/ABL TK inhibitors. Another important aspect 
is that many of the novel inhibitors are less speciﬁ  c drugs 
that do not only recognize BCR/ABL, but also (many) other 
key kinase-targets (Shah et al 2004; Martinelli et al 2005; 
Kimura et al 2005; Weisberg et al 2007b). The differential 
target proﬁ  les of TK inhibitors may also explain why several 
of them, when combined, produce synergistic antileukemic 
effects (Weisberg et al 2007a). In this regard it may be of 
great importance to learn which kinase-targets and related 
pathways play a predominant role in the biology and growth 
of CML stem cells. An important consideration in this regard 
is that the biology, function, and target expression proﬁ  les 
of CML stem cells may be similar but not identical to that 
of normal stem cells, and that the proﬁ  le may change during 
disease evolution, ie, progression to AP or BP (Zheng et al 
2006; Radich et al 2006; Villuendas et al 2006; Diaz-Blanco 
et al 2007).
Lastly, it has to be emphasized that the only established 
stem cell eradicating (=curative) therapy in CML remains 
SCT, and that SCT may also work in a group of patients 
with advanced CML (Goldman et al 1986; Silberman 1994; 
Gratwohl et al 1998; Dutcher and Wiernik 2000; Deininger 
2007). It also has been described that pre-transplant therapy 
with imatinib may be a reasonable approach in advanced 
CML (Giralt et al 2007; Weisser et al 2007). Moreover, SCT 
should remain an important option and major decision-point 
in treatment algorithms in imatinib-resistant CML (Jabbour 
et al 2006). Depending on the clinical situation and other fac-
tors, such therapy (SCT) may be combined with BCR/ABL 
TK inhibitors (Menzel et al 2007). Likewise, patients with 
imatinib-resistant CML in AP or BP who are young and 
have a suitable donor, may beneﬁ  t from targeted therapy 
with a second generation BCR/ABL TK inhibitor inducing 
remission or at least disease-reduction (debulking), followed 
by allogeneic SCT (Jabbour et al 2007a; Menzel et al 2007). 
As to whether such patients should also be treated with the 
same BCR/ABL TK inhibitors after SCT (maintenance, pro-
phylaxis) remains at present unknown. At least for patients 
with detectable BCR/ABL after SCT, maintenance therapy 
should be considered. Patients who fail SCT or relapse after 
SCT may also beneﬁ  t from new TK inhibitors. Whether such 
patients may even have a better outcome when receiving 
combination therapy (drug-combinations or donor lympho-
cytes plus a TK inhibitor) remains to be deﬁ  ned.
Pharmacologic aspects 
and pharmacologic resistance
Orally administered imatinib is rapidly (within 1–2 hours) 
and completely absorbed, with a bioavailability of 95%, 
and a peak plasma concentration reached after 2–4 hours 
(Cohen et al 2002; Peng et al 2005). The pharmacologic Biologics: Targets & Therapy 2007:1(4) 438
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half-life of the drug is approximately 18 hours (Cohen et al 
2002; le Coutre et al 2004; Peng et al 2004a, 2005). At a 
daily dose of 400 mg, imatinib plasma concentrations peak 
to about 2–3 μg/mL, with a trough level of approximately 
1 μg/mL (le Coutre et al 2004; Peng et al 2004a, 2005), which 
exceeds imatinib-doses required for complete inhibition of 
wt BCR/ABL TK activity (0.5 μg/mL = 1 μM). Imatinib is 
95% bound to human plasma proteins, mainly albumin 
and alpha1-acid glycoprotein (Cohen et al 2002; Peng et al 
2005). The drug is eliminated predominantly via the bile 
in form of metabolites (Cohen 2002; Gschwind et al 2005; 
Peng et al 2005). One of these metabolites, CGP74588, 
exhibits pharmacological activity comparable to the par-
ent-drug (Cohen et al 2002). Imatinib is metabolized via 
cytochrome (CYP) P450 isoenzymes, primarily CYP3A4, 
but also by other CYP 450 species (CYP3A5, CYP2D6). 
Therefore, imatinib can competitively inhibit the metabolism 
of drugs that are substrates of CYP P450 isoenzymes (Cohen 
et al 2002; O’Brien et al 2003). Vice versa, drugs that are 
metabolized via or are inducers of these CYP enzymes may 
inﬂ  uence the bioavailability of imatinib, and thus lead to 
changes (eg, decrease) in imatinib plasma concentrations 
(Cohen et al 2002; Bolton et al 2004; Dutreix et al 2004; Frye 
et al 2004). Also, hepatic and renal dysfunction may result in 
slight changes in imatinib concentrations in biological ﬂ  uids 
and tissues (Peng et al 2005; Pappas et al 2005; Eckel et al 
2005). However, these changes usually are mild and do not 
require dose-adjustments. Age, race, sex, and bodyweight 
have no documented inﬂ  uence on the pharmacokinetics or 
pharmacodynamics of imatinib (Peng et al 2005).
From experience in clinical trials, patients with CML are 
judged to be imatinib-resistant when response is lost or is not 
seen with a daily dose of 400 mg imatinib (Kantarjian et al 
2003; Baccarani et al 2006). Studies on pharmacokinetics 
and pharmacodynamics of imatinib in CML suggest that a 
minimum dose of imatinib of 350–400 mg daily is required 
to reach a constant effective drug concentration in plasma, 
that would block wt BCR/ABL (Peng et al 2004b). However, 
no detailed studies on tissue-concentrations of imatinib in 
various organs have been presented so far, and some of the 
tissues and organ-compartments (brain) may not be reached 
sufﬁ  ciently by imatinib. In addition, a number of genetic 
and other factors may inﬂ  uence the bioavailability of the 
drug (Peng et al 2005; Pappas et al 2005; Eckel et al 2005). 
Moreover, the expression of drug transporters and drug-
efﬂ  ux pumps, that are expressed in the apical membrane 
of the small intestine and the bile canalicular membrane, 
have been implicated in pharmacologic resistance (Burger 
and Nooter 2004; Burger et al 2005). All in all, a number 
of factors may inﬂ  uence the plasma- and tissue levels of 
imatinib, and under certain circumstances, may contribute 
to pharmacologic resistance.
More recent data suggest that pharmacologic resistance 
may indeed be of clinical relevance. In fact, it has been 
described that the trough plasma level of imatinib is associ-
ated with the rate of CCR and of major molecular responses 
(MMR) in patients with CML (Picard et al 2007). In particu-
lar, signiﬁ  cantly higher trough levels were found in patients 
with CCR and MMR (often 1 μg/ml) compared to those 
without CCR or MMR (often 1 μg/ml) (Picard et al 2007). 
An unresolved question is whether the different trough 
levels in the two groups of patients resulted from a primary 
defect(s) in bioavailability (true pharmacologic resistance) or 
from massive drug-uptake by residual CML cells in less well 
responding patients. Whatever the reason is, the observation 
of different trough levels may be of clinical signiﬁ  cance, 
and it seems appropriate to recommend that plasma trough 
levels are measured in patients with otherwise unexplained 
suboptimal response (or no response) to imatinib.
A number of different strategies have been proposed to 
overcome pharmacologic resistance against imatinib. Sus-
picion for pharmacologic resistance must be raised when 
cytogenetic (and molecular) response is lost or not achieved, 
no BCR/ABL mutations and no signs of clonal evolution are 
found, and trough imatinib levels are low. It is then important 
to ask for possible drug-interactions, patient´s complience, 
and concomitant disorders. After having excluded such 
causes, dose adjustments (increase) should be considered and 
may lead to a better response (Kantarjian et al 2003). Another 
potential strategy, that may become subject of future studies, 
would be to try to increase the imatinib uptake in the intestinal 
wall (and in other critical target cell populations), and thus 
bioavailability of the drug, or by imatinib with modulators 
of transport-proteins (Breedveld et al 2006).
‘Anatomic resistance’ against 
imatinib
A special problem with imatinib is its marginal accumula-
tion in the central nervous system (CNS) which is caused 
by low uptake via the blood-brain barrier (Takayama et al 
2002; Senior 2003; Dai et al 2003; Wolff et al 2003). The 
biochemical basis of poor uptake is not well understood. 
One hypothesis is that the abundant expression of MDR-1 
(P-glycoprotein) in cells forming the blood-brain barrier 
is associated with constant drug-efﬂ  ux (Dai et al 2003; 
Breedveld et al 2005; Breedveld et al 2006). Clinically, the Biologics: Targets & Therapy 2007:1(4) 439
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poor uptake into the CNS is reﬂ  ected by CNS relapses that 
occur in imatinib-treated patients (Abruzzese et al 2003; Leis 
et al 2004; Bornhäuser et al 2004; Rajappa et al 2004; Ryt-
ting and Wierda 2004; Matsuda et al 2005; Pavlu et al 2005; 
Kim et al 2006). This is a well known problem in lymphoid 
leukemias and in the lymphoid blast phase of CML. How-
ever, more recently, myeloid CNS relapses have also been 
described (Rytting and Wierda 2004; Aichberger et al 2007). 
Some of these CNS relapses occur even in patients with CCR 
(Bornhäuser et al 2004; Aichberger et al 2007).
A number of strategies have been proposed to treat and 
to prevent CNS relapses in CML. Once diagnosed, local 
therapy of the CNS relapse with intrathecal cytostatic drugs 
(cytarabine and others) and/or radiation seems an appropri-
ate therapeutic maneuver (Abruzzese et al 2003; Leis et al 
2004; Bornhäuser et al 2004; Rajappa et al 2004; Rytting and 
Wierda 2004; Matsuda et al 2005; Pavlu et al 2005; Kim et al 
2006; Aichberger et al 2007). In those with a concomitant 
systemic relapse, the additional replacement of imatinib by 
a second generation BCR/ABL inhibitor must be considered 
(Abdelhalim et al 2007; Aichberger et al 2007). Interestingly, 
for some of these emerging drugs (dasatinib, INNO-406), it 
has been described that they can cross the blood-brain barrier 
quite effectively in animal models (Wild et al 2004; Yokota 
et al 2007), and the same may hold true for patients with 
CML in CNS relapse (Abdelhalim et al 2007; Aichberger 
et al 2007). Therefore, it seems logic to consider the use of 
such new TK inhibitors as prophylaxis of CNS relapses as 
well. In case that the frequency of reported CNS relapses will 
further increase, such prophylactic therapy must be regarded 
as a mandatory approach. An alternative approach might be 
to increase the uptake of imatinib by applying modulators 
of drug transporters (eg, MDR-1).
BCR/ABL mutations
The predominant molecular defect that causes resistance 
against imatinib are point mutations in the BCR/ABL oncogene 
(Gorre et al 2001; von Bubnoff et al 2002; Barthe et al 2002; 
Branford et al 2002, 2003; Shah et al 2002; Hochhaus et al 
2002). The respective BCR/ABL mutants retain their kinase 
activity and their oncogenic potential, but usually display 
impaired or absent drug-binding capacity (Roumiantsev et al 
2002; Azam et al 2003; Cowan-Jacob et al 2004; Weisberg 
et al 2007b). Other mutants may be less oncogenic and may 
not play an important role in disease evolution (Griswold et al 
2006; Khorashad et al 2006). Most of the relevant mutations 
cluster within or in next vicinity to the imatinib-binding site, 
or are located in BCR/ABL domains critical to the topography 
and tertiary structure of the imatinib/ATP-binding site, with 
consecutive steric hindrance of drug-binding (Branford 
et al 2002, 2003; Shah et al 2002; Hochhaus et al 2002; 
Roumiantsev et al 2002; Azam et al 2003; Cowan-Jacob et al 
2004; O’Hare et al 2005, Weisberg et al 2007b). Examples of 
BCR/ABL residues that (when derived from mutated genes) 
directly inhibit imatinib-binding, are Thr315 and Phe317 
(Cowan-Jacob et al 2004; Weisberg et al 2007b). Other 
BCR/ABL mutations destabilize the inactive conformation of 
the nucleotide-binding loop (P-loop) or the DFG motif that 
binds to imatinib, thereby reducing imatinib-binding afﬁ  nity 
(Roumiantsev et al 2002; Cowan-Jacob et al 2004; Weisberg 
et al 2007b). Residues affecting imatinib-binding through 
destabilization of the inactive conformation include Glu255, 
Tyr253, and Gly250 in the P-loop of ABL (Cowan-Jacob et al 
2004; Weisberg et al 2007b).
More than 50 different mutations in BCR/ABL have 
been described (von Bubnoff et al 2002; Shah et al 2002; 
Hochhaus et al 2002; Cowan-Jacob et al 2004; O’Hare et al 
2005; Weisberg et al 2007b). These mutations cluster in four 
major regions of the oncogene, namley the phosphate-binding 
(P-loop) domain (examples: M224V, L248V, G250E/R, 
Q252R/H, Y253F/H, E255K/V), the imatinib-binding 
domain (F311L/I, T315I, F317L), the catalytic domain 
(M351T, E355G/D), and the activation loop domain (V379I, 
F382L, L387M, H396R/P) (Shah et al 2002; Branford 
et al 2003; Hochhaus et al 2002). Table 2 shows BCR/ABL 
mutations frequently detected in patients with imatinib-
resistant CML.
In most CML patients, BCR/ABL mutations may already 
be present in (stem cell) subclones before imatinib therapy 
is initiated (Roche-Lestienne et al 2002, 2003; Kreuzer 
et al 2003; Jiang et al 2007a). However, in some patients, 
the BCR/ABL mutation may not simply be revealed through 
selection by drug-therapy, but may represent a newly 
occurring defect. An unresolved question in this regard is 
whether treatment with imatinib or other (targeted) drugs 
can modulate (increase) the BCR/ABL mutation rate (muta-
genic potential of drug). The more likely scenario is that 
the rapid and sustained elimination of all (many) subclones 
by TK inhibitors is important and should counteract the 
development of new BCR/ABL mutations, because the size 
of the target cell population (CML stem cells) in which such 
mutations can develop, is constantly shrinking over time in 
responding patients.
Another unresolved question is how the wt BCR/ABL 
subclone is capable of suppressing (all) BCR/ABL mutants. 
This phenomenon may be explained by chalone-dependent Biologics: Targets & Therapy 2007:1(4) 440
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inhibition or may be related to the different oncogenic 
potencies of the mutants. Clinically, this phenomenon is of 
diagnostic importance, as BCR/ABL mutations may not be 
detectable at diagnosis but only after drug-induced selection 
of stem cell subclones.
As mentioned above, the various BCR/ABL mutants 
display different oncogenic (transforming) potential 
(Griswold et al 2006; Skaggs et al 2006; Weisberg et al 
2007a). Taking their in vitro activity into consideration, 
the following rank order of (oncogenic) potency is found: 
Y253F = E255K  wt BCR-ABL  T315I  H396P  
M351T  others. Thus, certain P loop mutations (Y253F, 
E255K) and the T315I mutation display a high oncogenic 
potential, which is consistent with the clinical observation 
of a poor outcome concerning overall and progression-free 
survival (Branford et al 2003; Soverini et al 2005; Nicolini 
et al 2006). However, not all P-loop mutations may be 
associated with a poor prognosis in CML (Jabbour et al 
2006). In particular, several of the BCR/ABL mutations are 
far less oncogenic, and some of them may not even exhibit 
a proliferative advantage over normal (stem) cells, and thus 
may not even cause overt CML (Khorashad et al 2006). 
These mutations should not count in the evaluation of drug 
resistance and the consecutive treatment plan in the same 
way as clinically relevant (oncogenic) mutations.
A number of different strategies have been proposed to 
treat patients with imatinib resistant CML, in whom BCR/
ABL mutations are detected. Treatment in these patients 
depends on several different factors, including the type 
(oncogenic potential) of the mutation, phase of disease, 
presence of other pro-oncogenic disease-features (clonal 
evolution), age, co-morbidity, overall status of the patient, 
and availability of a SCT donor in those who are eligible 
for high-dose therapy. With regard to BCR/ABL mutations, 
four categories are proposed and related to speciﬁ  c treatment 
recommendations: a) mutations that do not cause clinically 
overt resistance (recommendation: wait and watch if pos-
sible), b) mutants that have low oncogenic potential and may 
disappear (at least kept under control) upon dose-escalation 
(recommendation: increase imatinib from 400 to 600 or 800 
mg/day), c) non-T315I-mutants that are not expected to dis-
appear on imatinib dose-escalation (recommendation: switch 
from imatinib to a second generation BCR/ABL inhibitor: 
nilotinib or dasatinib), and d) the T315I mutant as well as 
a few other mutants that are also resistant against dasatinib 
and nilotinib (recommendation: high-dose chemotherapy 
or experimental drugs and proceed to SCT if possible). The 
majority of all imatinib-resistant patients are in group b and 
c. Therefore, recent efforts have focused on the development 
of new, more effective BCR/ABL TK inhibitors that can 
Table 2 BCR/ABL mutations detectable in CML patients treated with imatinib
Mutant IC50* may  beneﬁ  t from  IC50* IC50*
 imatinib  IM-dose-escalation** dasatinib nilotinib
no (wt)  250–500  -  0.8  13
M244V 1,600–3,100  yes  1.3  38
M244I 1,400  yes  nk  nk
G250E  1,000 (3,000) no  1.8  48
Q252H 1,300–2,900  yes  3.4  70
Y253H 4,000–17,000  no  1.3  450
Y253F 1,800–5,000  no  1.4  125
E255K 5,000–12,000  no  5.6  200
E255V 6,000–20,000  no  11  430
F311L 480–1,300  no  1.3  23
T315I  10,000 no  200  2,000
F317L 1,000–2,300  no  7.4  50
M351T 900–4,900  yes  1.1  15
M351I 1,600  yes  nk  nk
F359V 1,400–1,800  yes  2.2  175
E355G 2,000–2,400  yes  nk  nk
V379I 1,000–1,600  yes  0.8  51
L387M 1,000–1,100  yes  2  49
H396P 850–4,300  no  0.6  41
H396R 1,750–5,400  no  1.3  41
Notes: *IC50 values are given in nM and refer to published data obtained with Ba/F3 cells exhibiting wild type BCR/ABL or various BCR/ABL mutants using cell – proliferation 
assays (O’Hare et al 2005; Martinelli et al 2005); **recommendations are derived from Martinelli and colleagues (2005).
Abbreviations: IM, imatinib; wt, wild type; nk, not known.Biologics: Targets & Therapy 2007:1(4) 441
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overcome resistance. Among these are nilotinib (AMN107), 
dasatinib (BMS354825), INNO-406, and several others 
(Table 3). These drugs act on various imatinib-resistant 
BCR/ABL mutants and can produce complete hematologic 
and cytogenetic responses in patients with imatinib-resistant 
disease (Talpaz et al 2006; Kantarjian et al 2006; Weisberg 
et al 2006; Quintas-Cardama et al 2007; Hochhaus et al 
2007b; Cortes et al 2007; Guilhot et al 2007). Encouraging 
results have particularly been obtained in CP, but hemato-
logic and sometimes cytogenetic or molecular responses 
may also be seen in AP or BP. However, as stated above, 
not all BCR/ABL mutants are responsive to these inhibitors, 
and the relative potencies vary among drugs. Unfortunately, 
patients with the T315I mutant of BCR/ABL are clinically 
resistant against nilotinib and dasatinib, and also against most 
other available TK inhibitors (Talpaz et al 2006; Kantarjian 
et al 2006; Weisberg et al 2006). As mentioned above, for 
these patients, alternative therapies have to be considered. 
One possibility are novel kinase inhibitors or drugs that act 
independent of BCR/ABL (Martinelli et al 2005; Gumireddy 
et al 2005; Tauchi and Ohyashiki 2006; Jabbour et al 2007b) 
(Table 3). Another option is SCT with or without a second 
generation BCR/ABL inhibitor (Jabbour et al 2007a; Menzel 
et al 2007).
An interesting aspect is that BCR/ABL TK inhibitors, 
when applied in combination, may produce anti-leukemic 
effects on CML cells exhibiting BCR/ABL T315I, even 
if leukemic cells are resistant against single agents (White 
et al 2007; Weisberg et al 2007a). This phenomenon may be 
explained by additional drug targets expressed in these cells, 
by cooperative effects at BCR/ABL epitopes, or by increased 
drug accumulation in target cells (White et al 2007; Weisberg 
et al 2007a). Whether combinations of TK inhibitors will 
also induce long lasting remission in (all) patients with TK-
inhibitor resistant CML, remains at present unknown. It also 
remains unknown which of the new drugs, that have been 
described to counteract in vitro growth of leukemic cells 
exhibiting BCR/ABL T315I (Tseng et al 2005; Carter et al 
2005; Giles et al 2007; Cheetham et al 2007; Rahmani et al 
2007), will induce complete (and long lasting) cytogenetic 
remissions in vivo in these patients.
An important therapeutic consideration is prevention 
of occurrence (selection) of subclones carrying imatinib-
resistant BCR/ABL mutants. One approach may be to combine 
Table 3 Novel pharmacologic inhibitors proposed for imatinib-resistant CML
Drug name  Drug type  Known  active in cells bearing
 class  target(s)  BCR/ABL  T315I
Dasatinib (Sprycel)  TKI  Abl, Src, Lyn, Btk,  no
    Kit, PDGFR, ......
Nilotinib (Dasigna)  TKI  Abl, Kit, PDGFR, ..  no
SKI-606 (Bosutinib)  TKI  Abl, Src, ..  no
INNO-406 (NS-187)  TKI  Abl, Lyn, Kit, ..  no
AZD0530  TKI  Abl, Src, ..  no
AP23464  TKI  Abl, Src, ..  no
CGP76030  TKI  Abl, Src, ..  +/−*
PP1  TKI  Abk, Src, ..  +/−*
PD166326  TKI  Abl, Src, ..  no
ON012380  TKI  Abl, PDGFR, Lyn  yes
MK-0457 (VX-680),  AuK-I  Aurora-kinase  yes
other AuK-I
BIRB-796,  p38-I  p38 MAP kinase, (Abl)  no
43-9006 (sorafenib)  Kinase-I  multiple kinases, Mcl-1  yes
WP1130 -  ?  (Jak,  Abl-knock-down)  yes
various  hypomethyla-  re-expression of tumor  +/−
 ting  agents  suppressors
various  Hsp-I  Hsp32, Hsp70, Hsp90, ...  yes
various compounds  FTIs  RAS  +/−
various compounds  PI3K-I  PI3-kinase  yes
Rapamycin and its derivatives  mTOR-I  mTOR  yes
Notes: *relatively high drug concentrations needed to block growth of cells.
Abbreviations: TKI, tyrosine kinase inhibitor; PDGFR, platelet derived growth factor receptor; Hsp, heat shock proteins; FTI, farnesyl transferase inhibitor; mTOR, mam-
malian target of rapamycin.Biologics: Targets & Therapy 2007:1(4) 442
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TK inhibitors in an early phase of disease, similar to the 
situation in HIV-positive patients, where early intervention 
is performed using multiple drugs. Another strategy may be 
to combine novel TK inhibitors with a stem cell-attacking 
approach, like SCT or high-dose chemotherapy, or with 
stem cell-suppressing maintenance therapy (eg, interferon-
alpha).
Finally, several treatment concepts focus on the mobi-
lization of the immune system, with the ultimate goal to 
target residual leukemic (stem) cells (MRD) in CML (Li 
et al 2005; Westermann et al 2007; Volpe et al 2007; Peng 
et al 2007). In most instances, immunotherapy is combined 
with a BCR/ABL TK inhibitor. Whether such intervention 
may lead to the eradication of (all) relevant CML stem cell 
subclones remains to be elucidated.
Other BCR/ABL defects
Apart from BCR/ABL mutations, other defects in BCR/ABL 
may also contribute to resistance against imatinib. Such 
alternative defects include BCR/ABL gene duplications 
and -ampliﬁ  cations (le Coutre et al 2000; Weisberg and 
Grifﬁ  n 2000; Gorre et al 2001; Nguyen Khac et al 2002; 
Campbell et al 2002; Morel et al 2003; Gargallo et al 2003; 
Gadzicki et al 2005). These defects may be associated with 
(multiple) cytogenetic abnormalities (Gadzicki et al 2005; 
Pienkowski-Grela et al 2007), and several of these patients 
are in an accelerated phase or blast phase of CML (Tanaka 
et al 2000; Gadzicki et al 2005; Pienkowski-Grela et al 
2007). Therefore, in most cases, the contribution of ampliﬁ  ed 
BCR/ABL in the malignant process (progression) and in drug 
resistance remains uncertain. Nevertheless, some of these 
patients respond to elevated doses (or even standard doses) 
of imatinib, suggesting that the BCR/ABL defect may have 
pharmacologic and clinical impact.
BCR/ABL-independent molecular 
resistance
During disease, the CML clone may acquire additional 
BCR/ABL-independent molecular (genetic) defects and 
pro-oncogenic hits in stem cell subclones, which may lead to 
disease-progression. Such clonal evolution is often accompa-
nied by the occurrence of cytogenetic defects. Leukemic cells 
in these patients are frequently resistant against imatinib, and 
may exhibit aneuploidy, sometimes in form of a second Ph 
chromosome or trisomy 8 (+8) (Hochhaus et al 2002). Other 
cytogenetic defects that have been described in imatinib-
resistant CML include trisomy 6 (+6), +9, +12, +18, and 
monosomy 7 (−7) (Hochhaus et al 2002; Cortes et al 2003; 
Marktel et al 2003; O’Dwyer et al 2004). Most cytogenetic 
defects are considered to be of prognostic signiﬁ  cance con-
cerning survival in imatinib-treated patients (Cortes et al 
2003; Marktel et al 2003; O’Dwyer et al 2004). However, 
not all cytogenetic defects may lead to imatinib-resistance. 
Especially isolated chromosome defects may disappear or 
persist at stable (low) level without loss of hematologic 
response during therapy. In other patients, resistance may 
develop within short time.
The molecular defects that accompany cytogenetic 
abnormalities and may contribute to resistance against ima-
tinib, have not been deﬁ  ned yet. Therefore, at present, it is 
difﬁ  cult to predict the clinical impact of isolated cytogenetic 
defects for imatinib-treated patients. A special situation is 
the occurrence of cytogenetic defects in Ph-negative sub-
clones during imatinib therapy (Medina et al 2003; Terre 
et al 2004; Loriaux and Deininger 2004; Lin et al 2006; 
Navarro et al 2007; Jabbour et al 2007). One hypothesis is 
that these subclones derive from a very immature progeni-
tor that was involved in a pre-Ph (pre-BCR/ABL) phase of 
CML (Figure 1), and under certain circumstances can be 
activated (by additional hits) to transform into a secondary 
Ph-negative (but still monoclonal) neoplasm. Indeed, some 
of these patients may develop overt secondary disease (that 
may resemble a myelodysplastic syndrome, MDS or acute 
myeloid leukemia, AML), even if the Ph-positive (sub)clones 
are completely suppressed (Loriaux and Deininger 2004; 
Lin et al 2006; Navarro et al 2007; Jabbour et al 2007). The 
subclone hypothesis is supported by HUMARA analysis 
as well as the fact, that the karyotype abnormalities are the 
same as those detectable in Ph-positive subclones (Terre et al 
2004; Navarro et al 2007; Jabbour et al 2007). An alternative 
hypothesis is that Ph-negative clones develop independent 
of the primary disease (unrelated clone). Such hypothesis 
would pose the question as to whether imatinib exhibits a 
substantial mutagenic potential and can attack normal stem 
cells similar to conventional cytostatic drugs. So far, no clear 
evidence for such hypothesis has been presented, although 
single case reports have suggested that even transplanted 
normal stem cells may undergo transformation and accumu-
late cytogenetic defects during treatment with imatinib (Agis 
et al 2004). However, again, such additional clones may not 
be relevant clinically (in all patients), and these patients may 
still stay in a complete hematologic remission with normal 
blood counts over time (Agis et al 2004).
As mentioned above, little is known so far about speciﬁ  c 
molecular defects and mechanisms underlying BCR/ABL-
independent resistance to imatinib in CML, and especially Biologics: Targets & Therapy 2007:1(4) 443
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about defects that can lead to malignant transformation in 
subclones. In fact, although an extensive number of (poten-
tially deregulated) molecules and numerous mechanisms 
have been discussed, no speciﬁ  c recurrent gene defects that 
would explain transformation of CML into AP or BP have 
been identiﬁ  ed (Calabretta and Perrotti 2004; Melo and 
Barnes 2007). General pathogenetic factors that have been 
discussed as being involved in disease progression in CML 
include activation of (mutation-induced) signal transduction 
molecules (by mutations or oncogene activation), differentia-
tion arrest, genomic instability (deﬁ  ciency of DNA repair, 
mutator phenotype), telomer shortening, and loss of tumor 
suppressor function (Calabretta and Perrotti 2004; Melo and 
Barnes 2007). Some of these defects may be triggered in part 
also by BCR/ABL. Likewise, BCR/ABL has been implicated 
in hypermethylation of the genome, in deactivation of tumor 
suppressors, and in the hypermutation-status of leukemic 
cells (Neviani et al 2006; Melo and Barnes 2007). However, 
most of the secondary transforming hits in CML may be 
BCR/ABL-independent events. The (numerous) candidate 
genes potentially involved in disease progression in CML, 
and their function, have been reviewed elsewhere (Calabretta 
and Perrotti 2004; Melo and Barnes 2007).
So far, it remains unknown which of these defects and 
deregulated molecules may contribute to resistance against 
imatinib in CML. Respective preclinical and clinical studies 
are in progress and hopefully will reveal new important thera-
peutic targets in the near future. Such studies focus primarily 
on genes involved in the differentiation block, in abnormal 
signalling, in abnormal DNA repair, and in the deactivation 
of tumor suppressors (Martinelli et al 2005; Melo and Barnes 
2007). It is the hope for the future that these studies will 
lead to the development of new treatment strategies aimed 
at preventing disease-progression in CML. A likely scenario 
is that such novel therapies will then be combined with most 
effective BCR/ABL TK inhibitors.
Intolerance and side effects
An important aspect in the treatment of CML with imatinib 
or other BCR/ABL TK inhibitors, are side effects that may 
lead to dose-reductions and thus may predispose for the 
development of resistance. For imatinib, only a few major 
side effects have been reported, including transient edema 
formation and mild myelosuppression (Druker et al 2001a; 
Kantarjian H et al 2002; Barbany et al 2002; Talpaz et al 
2002; Sawyers et al 2002; O’Brien et al 2003). Other side 
effects such as hepatic dysfunction or cardiac problems are 
uncommon. However, some of these side effects may lead 
to dose reductions or even to drug withdrawal. Nilotinib 
(AMN107) also exhibits a favorable toxicity proﬁ  le, although 
rare adverse side effects such as an elevation in pancreatic 
enzymes, have been reported (Kantarjian et al 2006). With 
regard to dasatinib, a number of side effects have been 
reported using the proposed standard dose of 2 × 70 mg 
per os daily. These side effects include pleural and peri-
cardial effusions and myelosuppression (Talpaz et al 2006; 
Hochhaus et al 2007). Based on ﬁ  rst observations in clinical 
trials and unpublished data, the frequency of side effects 
may be lower when the dose of dasatinib is reduced, which 
points to the question as to whether the standard dose should 
be reconsidered. Notably, dasatinib is a most potent inhibi-
tor of leukemic cell growth in CML, and in many patients, 
the drug may still work at reduced dose levels (Talpaz et al 
2006; Hochhaus et al 2007). Some of the side effects may 
also be less frequent when the drug is administered once 
daily (1 × 140 mg instead of 2 × 70 mg).
For most other TK inhibitors, side effect proﬁ  les in CML 
patients remain to be established.
Clinical practice: Algorithm
Deﬁ  nitions for ‘suboptimal response’ and ‘drug-resistance’ 
in CML patients treated with imatinib are well established 
(Baccarani et al 2006). It is also well established, that 
patients with drug resistance should undergo restaging and 
BCR/ABL mutation analysis. In addition, the availability 
of a SCT donor should be (re)explored. The ﬁ  nal treatment 
plan will be based on a number of different variables, includ-
ing disease-speciﬁ  c factors (phase of disease, presence and 
type of BCR/ABL mutation, presence and type of additional 
chromosomal abnormalities, extramedullary involvement, 
lymphoid versus myeloid blasts), patient-related factors 
(age, ﬁ  tness, comorbidity, patients attitude, availability of a 
donor), and the overall situation in each case. After having 
collected all necessary information (including BCR/ABL 
mutations, and if required an imatinib trough level), a 
straight forward approach may be to estimate chances for 
long term disease-free survival (cure in young patients) 
with each therapeutic approach, and to weigh treatment-
associated mortality and morbidity against the chances 
for cure (long term disease-free survival). Depending on 
mutations and other features of the clone, some patients 
may beneﬁ  t from imatinib dose-escalation. In other cases, 
treatment has to be switched to dasatinib or nilotinib. Both 
drugs are registered and approved for treatment of imatinib-
resistant CML. The decision to introduce such therapy 
should be based on a thorough investigation for BCR/ABL Biologics: Targets & Therapy 2007:1(4) 444
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mutations, as treatment will fail when CML cells display 
the T315I mutant. For these patients, alternative treatment 
approaches have to be considered. In younger patients with a 
suitable donor who display BCR/ABL T315I or other highly 
resistant mutants, allogeneic SCT should be considered. 
When no donor is available or the patient is not considered 
ﬁ  t enough for SCT, new experimental drugs, some of them 
known to target BCR/ABL T315I, or drug combinations, 
should be offered in clinical trials.
Summary and future perspectives
Resistance against imatinib is an emerging problem in the 
treatment of CML. Dose-adjustments, new BCR/ABL-
targeting drugs, and other anti-leukemic approaches may be 
sufﬁ  cient to overcome resistance in many cases. A speciﬁ  c 
challenge remains the T315I mutant of BCR/ABL that is 
resistant against most available TK inhibitors. Other speciﬁ  c 
challenges are the intrinsic resistance of CML stem cells, 
clonal evolution, involvement of BCR/ABL-independent 
signalling pathways, and poor accumulation of imatinib in 
the central nervous system. For the future, new more effec-
tive BCR/ABL TK inhibitors, drug combinations, and drugs 
entering the blood–brain barrier, may be straightforward 
approaches to improve anti-CML therapy. Such approaches 
will also aim at preventing the occurrence of drug resistance 
in an early phase of CML. For those patients who fail drug 
therapy and are eligible, allogeneic stem cell transplanta-
tion with or without additional TK inhibitors, will remain 
an alternative option of treatment. The value of new future 
treatment strategies (immunotherapies, siRNA) remains at 
present unknown.
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